It is the third time in six years that the Panel has demanded that legislators classify cannabis as a Class C ‘soft’ drug, with minor, if any, criminal penalties.
Let’s hope the DEA’s answers are as illuminating as the questions being asked by Chairman Conyers.
As always, the first casualty in war is truth — and nowhere is this more evident than in Great Britain, where Prime Minister Gordon Brown appears intent on recriminalizing cannabis over the vehement objections of his own scientific advisory panel of experts and even the police.
Below is this week’s summary of pending state legislation and tips to help you become…
For the better part of ten years NORML (and the ACLU’s Drug Litigation Project) have been 1) monitoring increasing numbers of medical patients denied access to organ transplants for the singular reason that they test positive for cannabis and 2) researching litigation and legislative options to compel organ banks to stop discriminating against medical patients who use cannabis, most especially in states where medical marijuana patients are supposed to be protected by state laws.
A funny thing happens when the US government begrudgingly allows for double-blind, placebo-controlled clinical trials evaluating the therapeutic efficacy of inhaled cannabis.
Investigators discover time after time that it works!
In the New York Times today they of course attack the groups involved in bringing to the public’s attention the department’s overly aggressive and expensive enforcement of what are supposed to be decriminalized cannabis laws, and then make the amazing claim that there were not 350,000 cannabis-related arrests from 1997-2006, but a mere 8,770.
Best wishes and happy travels to one of America’s great authors of music, masters of the performance stage and American highways.